A pharmaceutical company wants to use deep learning to accelerate early-stage drug discovery. Given a disease target (a protein or a pathway), the system must predict which existing molecules are likely to bind (virtual screening), generate novel structures optimized for binding affinity and drug-likeness, and predict ADMET properties (absorption, distribution, metabolism, excretion, toxicity) so that compounds likely to fail later are filtered out early.
The constraints are brutal. Chemical space holds on the order of 
drug-like molecules, only a few thousand experimentally validated binding measurements exist for a typical novel target, and every molecule you nominate costs real money and weeks of chemistry to make and assay. Molecules that look optimal to a model but cannot be synthesized are worthless.
How would you design this system? Cover the molecular representation (SMILES strings vs molecular graphs vs 3D conformations), the property prediction model architecture, the generative model for novel compounds (VAE, GAN, diffusion, or autoregressive), the ADMET prediction pipeline, and how you evaluate generated molecules for validity, novelty, and synthesizability.
The Problem: the search space is astronomically large, the label set is tiny, and the wet lab can only test about a hundred molecules per round, so the system’s real job is choosing which hundred.
Answer
The design is a cost-ordered cascade closed by an active-learning loop: cheap learned scorers rank billions of candidates, progressively more expensive structure-based models rescore the survivors, an ADMET gate with calibrated uncertainty removes likely clinical failures, and a diverse batch of roughly a hundred molecules goes to the assay whose results retrain everything. Two decisions are pivotal. First, generation happens inside synthesizable space, conditioned on reactions and building blocks from a make-on-demand catalog, so a “novel” molecule always comes with a route. Second, every model output is treated as an acquisition function for a expensive experiment, not as truth, so the selection step optimizes expected confirmed hits per round under uncertainty rather than the top predicted potency.
(1) Cost-Ordered Cascade: spend microseconds on billions, seconds on millions, and minutes on thousands; only the final hundred reach the bench.
(2) Representation By Stage: 2D molecular graphs with a pretrained encoder for property prediction, 3D pocket-aware co-folding or docking only for rescoring the shortlist.
(3) Pretrain Then Multitask: self-supervised pretraining on millions of unlabeled molecules plus multitask fine-tuning across related assays beats training a single-target model on 2,000 labels.
(4) Synthesis-Constrained Generation: a pocket-conditioned generator that emits reaction and building-block choices, so validity and synthesizability are structural guarantees, not metrics you hope for.
(5) ADMET As A Gate, Not A Score: multitask ADMET heads plus hard structural alerts, with conformal abstention when a compound sits outside the applicability domain.
(6) Uncertainty-Aware Batch Selection: pick the assay batch for diversity and information gain, and feed every result, especially the inactives, back into training.
Figure 1: The discovery loop: cheap scoring first, structure-based rescoring on survivors, an ADMET and route gate before ordering, and assay results (hits and misses alike) retraining the scorer and the generator.
Clarify Before Designing:
(1) Target Knowledge: is there an experimental structure, a cryo-EM map, or only a predicted model, and is the binding site known?
(2) Starting Data: do we have a known ligand series to grow from, or is this a cold-start target with zero confirmed actives?
(3) Assay Economics: how many compounds per round, at what cost and turnaround, and is the primary assay binding or functional?
(4) Chemistry Constraints: in-house synthesis or catalog only, and which scaffolds are excluded for freedom-to-operate reasons?
(5) Property Profile: oral, CNS-penetrant, or injectable, and what safety margins (for example on hERG) are non-negotiable?
(6) Definition Of Success: is the handoff a confirmed hit rate, a number of novel chemotypes, or a potency threshold at a given selectivity?
Leave a Reply